Mette Bjerre

Adiponectin, type 2 diabetes and cardiovascular risk

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Søren Lindberg, Bispebjerg University Hospital, Copenhagen, Denmark.
  • ,
  • Jan Skov Jensen, Institut for Klinisk Medicin, Danmark
  • Mette Bjerre
  • Sune Ammentorp Haahr-Pedersen, Institut for Klinisk Medicin, Danmark
  • Jan Frystyk
  • Allan Flyvbjerg, Danmark
  • Søren Galatius, Institut for Klinisk Medicin, Danmark
  • Jørgen Jeppesen, Kirurgi og Intern Medicin, Danmark
  • Rasmus Mogelvang
Adiponectin is viewed as an insulin-sensitizing hormone with anti-inflammatory effects. In accordance, plasma adiponectin is decreased in metabolic disorders including type 2 diabetes mellitus (T2DM). However, in spite of the apparently beneficially effects, recent data from large prospective studies have consistently linked high adiponectin levels with increased cardiovascular (CV) disease and mortality, thus questioning the positive view on adiponectin. Accordingly, we investigated the relationship between adiponectin, incident T2DM and subsequently CV events.
OriginalsprogEngelsk
TidsskriftEuropean Journal of Preventive Cardiology
Vol/bind22
Nummer3
Sider (fra-til)276-83
Antal sider8
ISSN2047-4873
DOI
StatusUdgivet - 1 nov. 2015

Se relationer på Aarhus Universitet Citationsformater

ID: 71047869